Cargando…

Human and mouse non‐targeted metabolomics identify 1,5‐anhydroglucitol as SGLT2‐dependent glycemic marker

Detalles Bibliográficos
Autores principales:	Kappel, Ben A., Moellmann, Julia, Thiele, Kirsten, Rau, Matthias, Artati, Anna, Adamski, Jerzy, Ghesquiere, Bart, Schuett, Katharina, Romeo, Francesco, Stoehr, Robert, Marx, Nikolaus, Federici, Massimo, Lehrke, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236115/ https://www.ncbi.nlm.nih.gov/pubmed/34185398 http://dx.doi.org/10.1002/ctm2.470

Ejemplares similares

Non‐targeted metabolomics identify polyamine metabolite acisoga as novel biomarker for reduced left ventricular function
por: Puetz, Andreas, et al.
Publicado: (2021)

The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy
por: Schuett, Katharina, et al.
Publicado: (2023)

Cross-omics analysis revealed gut microbiome-related metabolic pathways underlying atherosclerosis development after antibiotics treatment
por: Kappel, Ben Arpad, et al.
Publicado: (2020)

Rational diagnoses of diabetes: the comparison of 1,5-anhydroglucitol with other glycemic markers
por: Malkan, Umit Yavuz, et al.
Publicado: (2015)

High-Risk Cardiovascular Patients: Clinical Features, Comorbidities, and Interconnecting Mechanisms
por: Schuett, Katharina Andrea, et al.
Publicado: (2015)

Gut-Derived Metabolite Indole-3-Propionic Acid Modulates Mitochondrial Function in Cardiomyocytes and Alters Cardiac Function
por: Gesper, Maren, et al.
Publicado: (2021)

SGLT5 is the renal transporter for 1,5-anhydroglucitol, a major player in two rare forms of neutropenia
por: Diederich, Jennifer, et al.
Publicado: (2023)

Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitol
por: Lee, Ji-Eun
Publicado: (2015)

Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes – Data from a randomized, placebo-controlled study
por: Rau, Matthias, et al.
Publicado: (2022)

1,5-Anhydroglucitol as a Useful Marker for Assessing Short-Term Glycemic Excursions in Type 1 Diabetes
por: Seok, Hannah, et al.
Publicado: (2015)

Measurement of 1,5-anhydroglucitol in blood and saliva: from non-targeted metabolomics to biochemical assay
por: Halama, Anna, et al.
Publicado: (2016)

Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study
por: Rau, Matthias, et al.
Publicado: (2021)

Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality
por: Selvin, Elizabeth, et al.
Publicado: (2016)

Serum 1,5-Anhydroglucitol Concentrations Are a Reliable Index of Glycemic Control in Type 2 Diabetes With Mild or Moderate Renal Dysfunction
por: Kim, Won Jun, et al.
Publicado: (2012)

Relationship of glycemic control markers - 1,5 anhydroglucitol, fructosamine, and glycated hemoglobin among Asian Indians with different degrees of glucose intolerance
por: Pramodkumar, Thyparambil Aravindakshan, et al.
Publicado: (2016)

Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure
por: Thiele, Kirsten, et al.
Publicado: (2022)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
por: Sayour, Alex Ali, et al.
Publicado: (2021)

Peptide YY (PYY) Is Associated with Cardiovascular Risk in Patients with Acute Myocardial Infarction
por: Haj-Yehia, Elias, et al.
Publicado: (2020)

Data for serum 1,5 anhydroglucitol concentration in different populations
por: Welter, Marciane, et al.
Publicado: (2018)

The gut hormone glucose-dependent insulinotropic polypeptide is downregulated in response to myocardial injury
por: Kahles, Florian, et al.
Publicado: (2022)

Reduced post-operative DPP4 activity associated with worse patient outcome after cardiac surgery
por: Noels, Heidi, et al.
Publicado: (2018)

1,5-Anhydroglucitol as a Marker of Acute Hyperglycemia in Cardiovascular Events
por: Migała, Marta, et al.
Publicado: (2022)

Effects of Acute and Chronic Resistance Exercise on the Skeletal Muscle Metabolome
por: Gehlert, Sebastian, et al.
Publicado: (2022)

Association of Glucose‐Dependent Insulinotropic Polypeptide Levels With Cardiovascular Mortality in Patients With Acute Myocardial Infarction
por: Kahles, Florian, et al.
Publicado: (2021)

Genome-wide association studies with metabolomics
por: Adamski, Jerzy
Publicado: (2012)

BEMER Electromagnetic Field Therapy Reduces Cancer Cell Radioresistance by Enhanced ROS Formation and Induced DNA Damage
por: Storch, Katja, et al.
Publicado: (2016)

Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors
por: Verma, Subodh, et al.
Publicado: (2018)

Value of serum 1,5-anhydroglucitol measurements in childhood obesity in the continuum of diabetes
por: Yoo, Ha Yeong, et al.
Publicado: (2015)

Salivary 1,5-Anhydroglucitol and Vitamin Levels in Relation to Caries Risk in Children
por: Syed, Sadatullah, et al.
Publicado: (2019)

Finding the clinical utility of 1,5-anhydroglucitol among primary care practitioners
por: Peabody, John, et al.
Publicado: (2020)

CETP and SGLT2 inhibitor combination therapy improves glycemic control
por: Khomtchouk, Bohdan B., et al.
Publicado: (2023)

Metabolomics of Ramadan fasting: an opportunity for the controlled study of physiological responses to food intake
por: Mathew, Sweety, et al.
Publicado: (2014)

1,5-Anhydroglucitol, an indicator of short term glycaemic control, is the most discriminatory metabolomic marker in adolescents with type 1 diabetes compared to control subjects
por: Conwell, Louise S, et al.
Publicado: (2015)

SGLT2 inhibitors in heart failure and type 2 diabetes: from efficacy in trials towards effectiveness in the real world
por: Marx, Nikolaus, et al.
Publicado: (2023)

Association between a biomarker of glucose spikes, 1,5-anhydroglucitol, and cancer mortality
por: Kira, Sakurako, et al.
Publicado: (2020)

Metabolomic profiling implicates adiponectin as mediator of a favorable lipoprotein profile associated with NT-proBNP
por: Masuch, Annette, et al.
Publicado: (2018)

Evaluation of Serum 1,5 Anhydroglucitol Levels as a Clinical Test to Differentiate Subtypes of Diabetes
por: Pal, Aparna, et al.
Publicado: (2010)

1,5-Anhydroglucitol Predicts Mortality in Patients with HBV-Related Acute-on-chronic Liver Failure
por: Zhang, Lingjian, et al.
Publicado: (2022)

Post-cardiac injury syndrome after transcatheter mitral valve repair using MitraClip system: a case report
por: Alachkar, Mhd Nawar, et al.
Publicado: (2020)

Trans-right ventricle and transpulmonary metabolite gradients in human pulmonary arterial hypertension
por: Chouvarine, Philippe, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6ds6b54ltnsmg4adpqv2j46ls7